Maria Cristina Manara, Francesca Bruzzese, Laura Formentini, Lorena Landuzzi, Laura Pazzaglia, Maria Antonella Laginestra, Marianna Carrabotta, Maria Serena Roca, Federica Iannelli, Laura Grumetti, Laura Addi, Alessandro Parra, Camilla Cristalli, Michela Pasello, Alberto Bavelloni, Francesca Carreras, Francesca Ruzzi, Giuseppe Bianchi, Marco Gambarotti, Alberto Righi, Alfredo Budillon, Pier-Luigi Lollini, Katia Scotlandi
{"title":"一组患者来源的异种移植物和细胞系的基因组分析鉴定了伊沙皮酮是一种抗化疗耐药骨肉瘤的活性药物。","authors":"Maria Cristina Manara, Francesca Bruzzese, Laura Formentini, Lorena Landuzzi, Laura Pazzaglia, Maria Antonella Laginestra, Marianna Carrabotta, Maria Serena Roca, Federica Iannelli, Laura Grumetti, Laura Addi, Alessandro Parra, Camilla Cristalli, Michela Pasello, Alberto Bavelloni, Francesca Carreras, Francesca Ruzzi, Giuseppe Bianchi, Marco Gambarotti, Alberto Righi, Alfredo Budillon, Pier-Luigi Lollini, Katia Scotlandi","doi":"10.1186/s13046-025-03440-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"44 1","pages":"195"},"PeriodicalIF":12.8000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235892/pdf/","citationCount":"0","resultStr":"{\"title\":\"Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma.\",\"authors\":\"Maria Cristina Manara, Francesca Bruzzese, Laura Formentini, Lorena Landuzzi, Laura Pazzaglia, Maria Antonella Laginestra, Marianna Carrabotta, Maria Serena Roca, Federica Iannelli, Laura Grumetti, Laura Addi, Alessandro Parra, Camilla Cristalli, Michela Pasello, Alberto Bavelloni, Francesca Carreras, Francesca Ruzzi, Giuseppe Bianchi, Marco Gambarotti, Alberto Righi, Alfredo Budillon, Pier-Luigi Lollini, Katia Scotlandi\",\"doi\":\"10.1186/s13046-025-03440-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":50199,\"journal\":{\"name\":\"Journal of Experimental & Clinical Cancer Research\",\"volume\":\"44 1\",\"pages\":\"195\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235892/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Experimental & Clinical Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13046-025-03440-5\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental & Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13046-025-03440-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma.
期刊介绍:
The Journal of Experimental & Clinical Cancer Research is an esteemed peer-reviewed publication that focuses on cancer research, encompassing everything from fundamental discoveries to practical applications.
We welcome submissions that showcase groundbreaking advancements in the field of cancer research, especially those that bridge the gap between laboratory findings and clinical implementation. Our goal is to foster a deeper understanding of cancer, improve prevention and detection strategies, facilitate accurate diagnosis, and enhance treatment options.
We are particularly interested in manuscripts that shed light on the mechanisms behind the development and progression of cancer, including metastasis. Additionally, we encourage submissions that explore molecular alterations or biomarkers that can help predict the efficacy of different treatments or identify drug resistance. Translational research related to targeted therapies, personalized medicine, tumor immunotherapy, and innovative approaches applicable to clinical investigations are also of great interest to us.
We provide a platform for the dissemination of large-scale molecular characterizations of human tumors and encourage researchers to share their insights, discoveries, and methodologies with the wider scientific community.
By publishing high-quality research articles, reviews, and commentaries, the Journal of Experimental & Clinical Cancer Research strives to contribute to the continuous improvement of cancer care and make a meaningful impact on patients' lives.